Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma Trading AD's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €0.24.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €0.73.
During the past 12 months, Sopharma Trading AD's average earnings per share (NRI) Growth Rate was -0.80% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 33.30% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 40.10% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 17.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Sopharma Trading AD's EPS without NRI or its related term are showing as below:
FRA:6YH'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9.9 Med: 14.2 Max: 50.8
Current: 33.3
During the past 13 years, Sopharma Trading AD's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 50.80% per year. The lowest was -9.90% per year. And the median was 14.20% per year.
FRA:6YH's 3-Year EPS without NRI Growth Rate is ranked better than 82.18% of 101
companies
in the Medical Distribution industry
Industry Median: 2.6
vs FRA:6YH: 33.30
Sopharma Trading AD's EPS (Basic) for the
three
months ended in Mar. 2026 was €0.24.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.76.
Sopharma Trading AD (FRA:6YH) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Sopharma Trading AD EPS without NRI Related Terms
Sopharma Trading AD EPS without NRI Historical Data
* Premium members only.
The historical data trend for Sopharma Trading AD's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6YH vs MCK, CAH, COR: EPS without NRI Comparison
For the Medical Distribution subindustry, Sopharma Trading AD's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma Trading AD PE Ratio without NRI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Sopharma Trading AD's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma Trading AD (FRA:6YH) has a EPS without NRI of €0.73 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sopharma Trading AD and its competitors. According to the industry distribution chart, Sopharma Trading AD ranks #18 out of 101 companies in the Medical Distribution industry, placing it in the top 17.8%.
Is Sopharma Trading AD's EPS without NRI too high?
Sopharma Trading AD's current EPS without NRI is €0.73. Based on the distribution chart, Sopharma Trading AD ranks #18 out of 101 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sopharma Trading AD has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's EPS without NRI compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma Trading AD ranks #18 out of 101 companies for EPS without NRI. This places Sopharma Trading AD in the top 18% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 2.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Distribution company?
The median EPS without NRI among Medical Distribution companies is 2.60, based on 101 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sopharma Trading AD and its competitors. For the Medical Distribution industry, the median EPS without NRI is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current EPS without NRI is €0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Sopharma Trading AD (FRA:6YH) has a current EPS without NRI of €0.73. The stock's GF Value™ is €7.38, compared to a current price of €2.74 — trading 62.9% below its estimated fair value. The current EPS without NRI is €0.73. Sopharma Trading AD's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Sopharma Trading AD (FRA:6YH), the current EPS without NRI is €0.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma Trading AD (FRA:6YH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued.
The current stock price of €2.74 is trading 62.9% below its estimated GF Value™ of €7.38.
Key valuation signals for FRA:6YH:
EPS without NRI: €0.73
GF Value™: €7.38 vs. price of €2.74 (62.9% below fair value)
No single metric tells the full story. See the FRA:6YH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
82GF Score
Get the complete analysis for FRA:6YH
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YH has been successfully added to your 
